Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity (Q35130984)

6 August 2017

1 reference

title

Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity (English)

1 reference

6 August 2017

Jennifer E Schwartz

1 reference

6 August 2017

Andrew M Yeager

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Pediatric Transplantation

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

168-178

1 reference

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

Identical-twin bone marrow transplants for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Outcome after allogeneic bone marrow transplant for leukemia in older adults

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Changing Trends in Allogeneic Bone Marrow Transplantation for Leukemia in the 1980s

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Pathophysiologic mechanisms of acute graft-vs.-host disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Mini-allografts: ongoing trials in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Bone marrow transplantation without myeloablation for sickle cell disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Non-myeloablative transplants for malignant disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2003.00016.X

7 January 2021

10.1034/J.1399-3046.2003.00016.X

Identifiers

DOI

1 reference

6 August 2017

1 reference